Your browser doesn't support javascript.
loading
Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
Hamy, A-S; Pierga, J-Y; Sabaila, A; Laas, E; Bonsang-Kitzis, H; Laurent, C; Vincent-Salomon, A; Cottu, P; Lerebours, F; Rouzier, R; Lae, M; Reyal, F.
Afiliação
  • Hamy AS; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.
  • Pierga JY; INSERM, U932 Immunity and Cancer, Paris.
  • Sabaila A; Department of Medical Oncology, Institut Curie, Paris.
  • Laas E; Faculty of Medicine, Paris Descartes University, Paris.
  • Bonsang-Kitzis H; Departments of Surgery, Institut Curie, Paris.
  • Laurent C; Departments of Surgery, Institut Curie, Paris.
  • Vincent-Salomon A; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.
  • Cottu P; INSERM, U932 Immunity and Cancer, Paris.
  • Lerebours F; Departments of Surgery, Institut Curie, Paris.
  • Rouzier R; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.
  • Lae M; INSERM, U932 Immunity and Cancer, Paris.
  • Reyal F; Department of Pathology, Institut Curie, Paris, France.
Ann Oncol ; 28(9): 2233-2240, 2017 Sep 01.
Article em En | MEDLINE | ID: mdl-28911063

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Linfócitos do Interstício Tumoral / Células Estromais / Genes erbB-2 / Terapia Neoadjuvante / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Linfócitos do Interstício Tumoral / Células Estromais / Genes erbB-2 / Terapia Neoadjuvante / Antineoplásicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article